Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by FWG Holdings LLC

FWG Holdings LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% during the third quarter, Holdings Channel.com reports. The firm owned 3,591 shares of the medical equipment provider’s stock after purchasing an additional 101 shares during the period. FWG Holdings LLC’s holdings in Zimmer Biomet were worth $372,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at approximately $28,000. Crewe Advisors LLC acquired a new position in Zimmer Biomet during the 1st quarter worth about $31,000. Bangor Savings Bank purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet during the 2nd quarter worth approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Zimmer Biomet in the 2nd quarter valued at approximately $43,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wolfe Research assumed coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. cut their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research report on Monday, September 16th. Oppenheimer dropped their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, BTIG Research lowered their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Price Performance

Shares of ZBH opened at $113.02 on Tuesday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock’s 50 day moving average is $106.45 and its two-hundred day moving average is $109.94. Zimmer Biomet Holdings, Inc. has a twelve month low of $101.47 and a twelve month high of $133.90. The firm has a market capitalization of $22.50 billion, a PE ratio of 21.49, a P/E/G ratio of 2.07 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.65 earnings per share. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.